

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

HOSPIRA, INC., and
SAMSUNG BIOEPIS CO., LTD.,¹

Petitioners,

v.

GENENTECH, INC.,
Patent Owner,

Case IPR2017-01489

Patent 6,407,213

REPLY DECLARATION OF BENJAMIN A. LASKY

¹ Samsung Bioepis Co. Ltd.'s IPR2017-02140 has been joined with this proceeding.

(IPR2017-02140, Paper 40)

I, Benjamin A. Lasky, declare under penalty of perjury as follows:

1. I am an attorney and Partner of the law firm Kirkland & Ellis, LLP.
2. I make this Declaration in support of Petitioners' Reply to Patent Owner Genentech's Response.
3. Exhibit 1693 is a true and correct copy of Foote, *Humanized Antibodies*, 61(269) NOVA ACTA LEOPOLDINA 103–110 (1989).
4. Exhibit 1694 is a true and correct copy of Kolbinger, *et al.*, *Humunization of a Mouse Anti-Human IgE Antibody: A Potential Therapeutic for IgE-Mediated Allergies*, 6(8) PROTEIN ENGINEERING 971–980 (1993).
5. Exhibit 1695 is a true and correct copy of DAVID J. KING, APPLICATIONS AND ENGINEERING OF MONOCLONAL ANTIBODIES (1998).
6. Exhibit 1696 is a true and correct copy of Presta, *Humanized Monoclonal Antibodies*, 29 ANN. REP. IN MED. CHEMISTRY, 317–324 (1994).
7. Exhibit 1697 is a true and correct copy of Deposition Transcript of Ian A. Wilson, dated April 21, 2018.
8. Exhibit 1698 is a true and correct copy of Deposition Transcript of Paul J. Carter, dated April 27, 2018.
9. Exhibit 1699 is a true and correct copy of Deposition Transcript of Leonard G. Presta, dated May 1, 2018.

10. Exhibit 1700 is a true and correct copy of Deposition Transcript of Irene Loeffler, dated May 1, 2018.

11. Exhibit 1701 is a true and correct copy of Deposition Transcript of John B. Ridgway Brady, dated April 27, 2018.

12. Exhibit 1706 is a true and correct copy of Foote & Winter, *Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops*, 224 J. MOLECULAR BIOLOGY 487–499 (1991).

13. Exhibit 1707 is a true and correct copy of Hale *et al.*, *Remission Induction in Non-Hodgkin Lymphoma with Reshaped Human Monoclonal Antibody Campath-1H*, 332 LANCET 1394–1399 (1988).

14. Exhibit 1708 is a true and correct copy of Mathieson *et al.*, *Monoclonal Antibody Therapy in Systemic Vasculitis*, 323(4) NEW ENG. J. MED. 250–254 (1990).

15. Exhibit 1709 is a true and correct copy of Kyle *et al.*, *Humanized Monoclonal Antibody Treatment in Rheumatoid Arthritis*, 18(11) J. RHEUMATOLOGY 1737–1738 (1991).

16. Exhibit 1710 is a true and correct copy of Brown, Jr. *et al.*, *Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor Prolongs Primate Cardiac Allograft Survival*, 88 PROC. NAT'L. ACAD. SCI. U.S. 2663–2667 (1991).

17. Exhibit 1711 is a true and correct copy of Havrdova, *et. al.*, *Alemtuzumab in the Treatment of Multiple Sclerosis: Key Clinical Trial Results and Considerations for Use*, 8(1) THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS 31–45 (2015).

18. I declare under penalty of perjury under the laws of the United States of America that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Executed on May 25, 2018, in New York, New York.

/Benjamin A. Lasky/
Benjamin A. Lasky